Erste Asset Management GmbH Takes Position in Trevi Therapeutics, Inc. $TRVI

Erste Asset Management GmbH bought a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 90,000 shares of the company’s stock, valued at approximately $1,154,000. Erste Asset Management GmbH owned 0.07% of Trevi Therapeutics as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Pivotal bioVenture Partners Investment Advisor LLC grew its position in shares of Trevi Therapeutics by 9.7% in the third quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,256,782 shares of the company’s stock valued at $11,500,000 after purchasing an additional 110,672 shares during the period. Nan Fung Trinity HK Ltd. boosted its position in Trevi Therapeutics by 924.2% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 917,450 shares of the company’s stock worth $11,486,000 after acquiring an additional 827,875 shares during the last quarter. F m Investments LLC acquired a new position in Trevi Therapeutics during the fourth quarter worth about $3,023,000. Pictet Asset Management Holding SA boosted its position in Trevi Therapeutics by 13,507.0% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,532,013 shares of the company’s stock worth $19,181,000 after acquiring an additional 1,520,754 shares during the last quarter. Finally, Comerica Bank boosted its position in Trevi Therapeutics by 19,481.8% during the fourth quarter. Comerica Bank now owns 83,027 shares of the company’s stock worth $1,039,000 after acquiring an additional 82,603 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Trading Down 1.4%

Shares of Trevi Therapeutics stock opened at $13.40 on Thursday. The company has a fifty day simple moving average of $13.88 and a 200-day simple moving average of $12.46. Trevi Therapeutics, Inc. has a 12-month low of $5.41 and a 12-month high of $16.12. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -41.88 and a beta of 1.04.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). On average, analysts forecast that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Analyst Ratings Changes

TRVI has been the topic of a number of recent research reports. Stifel Nicolaus set a $30.00 price target on shares of Trevi Therapeutics in a research report on Friday, May 8th. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. JonesTrading reduced their price target on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, March 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Monday, April 20th. Finally, Wall Street Zen downgraded shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $22.90.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.